✦ LIBER ✦

A522 Clinical Efficacy of Velcade/CTD Regimen in Patients with Relapsed or Refractory Multiple Myeloma

✍ Scribed by Kim, YK; Lee, JJ; Sohn, SK; Joo, YD; Shin, HJ; Chung, JS; Moon, JH; Chae, YS; Ahn, JS; Yang, DH; Kim, HJ

Book ID: 118629384
Publisher: CIG Media Group, LP.
Year: 2009
Tongue: English
Weight: 85 KB
Volume: 9
Category: Article
ISSN: 1557-9190
DOI: 10.1016/s1557-9190(11)70611-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical efficacy of a bortezomib, cyclo

Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study

✍ Yeo-Kyeoung Kim; Sang-Kyun Sohn; Jae-Hoon Lee; Deok-Hwan Yang; Joon-Ho Moon; Jae 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 175 KB

A Prospective, Open-Label Safety and Eff

A Prospective, Open-Label Safety and Efficacy Study of Combination Treatment with Bortezomib (PS-341, Velcade™) and Melphalan in Patients with Relapsed or Refractory Multiple Myeloma

✍ Yang, Hank H.; Vescio, Robert; Schenkein, David; Berenson, James R. 📂 Article 📅 2003 🏛 CIG Media Group, LP. 🌐 English ⚖ 129 KB

Lenalidomide in combination with dexamet

Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment

✍ Ulrike Klein; Kai Neben; Thomas Hielscher; Christiane Heiß; Anthony D. Ho; Hartm 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 204 KB

Phase II trial of temsirolimus in patien

Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma

✍ Sherif S. Farag; Shuhong Zhang; Buffy S. Jansak; Xiaojing Wang; Eric Kraut; Kenn 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 508 KB

In a phase II trial, 16 patients with relapsed refractory multiple myeloma received temsirolimus 25mg I.V. weekly until progression. One partial response and 5 minor responses were observed for a total response rate of 38%. The median time to progression was 138 days. Grade 3-4 toxicity included fat

Phase 2 study of arsenic trioxide in pat

Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma

✍ Mohamad A. Hussein; Mansoor Saleh; Farhad Ravandi; James Mason; Robert M. Rifkin 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB

Efficacy of single-agent bortezomib vs.

Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison

✍ H. Miles Prince; Michael Adena; Dell Kingsford Smith; Judy Hertel 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 593 KB